Key facts
- It has raised $500K; the latest was Grant ($490K) in Dec 2025.
- Notable investors include EUREKA Eurostars, Leiden University Medical Center, Libertatis Ergo Holding (LEH), LifeSciences@Work, PLNT. — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for StemX Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for StemX Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About StemX Bio
Developer of human pancreatic microtissues designed to accelerate early drug discovery and development. The company's features robust, reproducible microtissues derived from human stem cells, incorporating key pancreatic cell types for high-throughput screening, enabling researchers to reduce false positives, streamline drug testing, and advance diabetes research with improved physiological relevance and ethical integrity.
- Sector
- Healthcare
- HQ
- Leiden, Netherlands
- Founded
- 2024
- Employees
- 8
- Website
- stemxbio.com/
- Ownership
- Privately Held (backing)
StemX Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in StemX Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on StemX Bio in its N-PORT filings yet. We sweep new filings monthly.